Get the Stockscreener App
11.21
4.60%
-0.54
After Hours:
11.15
-0.06
-0.54%
Phathom Pharmaceuticals Inc stock is traded at $11.21, with a volume of 1.44M.
It is down -4.60% in the last 24 hours and up +8.00% over the past month.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$11.75
Open:
$11.73
24h Volume:
1.44M
Relative Volume:
1.25
Market Cap:
$795.28M
Revenue:
$114.04M
Net Income/Loss:
$-330.15M
P/E Ratio:
-2.37
EPS:
-4.73
Net Cash Flow:
$-274.85M
1W Performance:
-5.32%
1M Performance:
+8.00%
6M Performance:
+84.38%
1Y Performance:
-40.12%
1-Day Range:
$11.11
$11.95
1-Week Range:
$10.84
$11.97
52-Week Range:
$2.21
$19.50
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals Inc
Sector
Industry
Phone
(877) 742-8466
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
11.21 | 833.59M | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-24 | Initiated | Stifel | Buy |
| Jan-05-24 | Reiterated | Needham | Buy |
| Aug-09-23 | Initiated | H.C. Wainwright | Buy |
| May-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-13-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| May-06-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-12-21 | Upgrade | Goldman | Sell → Neutral |
| Feb-17-21 | Initiated | BMO Capital Markets | Outperform |
| Feb-02-21 | Initiated | Guggenheim | Buy |
| Jun-26-20 | Downgrade | Goldman | Neutral → Sell |
| Nov-20-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Goldman | Neutral |
| Nov-19-19 | Initiated | Jefferies | Buy |
| Nov-19-19 | Initiated | Needham | Buy |
View All
Phathom Pharmaceuticals Inc Stock (PHAT) Latest News
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 4.1%Time to Sell? - MarketBeat
MACD Signal: How does C F Financial Corporation correlate with NasdaqIPO Watch & AI Based Trade Execution Alerts - khodrobank.com
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why - Yahoo Finance
Dip Buying: What is Phathom Pharmaceuticals Incs book value per shareJuly 2025 Gainers & Entry Point Confirmation Alerts - khodrobank.com
Meme Stocks: Does Phathom Pharmaceuticals Inc. stock have upside surprise potentialEarnings Overview Summary & Community Verified Trade Alerts - khodrobank.com
Real time alert setup for Phathom Pharmaceuticals Inc. performanceEarnings Recap Summary & High Conviction Buy Zone Alerts - newser.com
Bull Bear: Can Phathom Pharmaceuticals Inc. weather a recessionTrade Volume Summary & Technical Entry and Exit Alerts - khodrobank.com
Woodline Partners LP Has $4.71 Million Stock Holdings in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Investor Mood: Is Phathom Pharmaceuticals Inc backed by strong institutional buyingDay Trade & Fast Entry and Exit Trade Plans - khodrobank.com
Quarterly Trades: Is Phathom Pharmaceuticals Inc backed by strong institutional buyingJuly 2025 Volume & Fast Entry High Yield Tips - khodrobank.com
Jobs Data: What hedge funds are buying Phathom Pharmaceuticals Inc2025 Historical Comparison & Precise Entry and Exit Recommendations - khodrobank.com
Recap Report: How correlated is Phathom Pharmaceuticals Inc to the S P5002025 Market Outlook & Accurate Entry and Exit Point Alerts - khodrobank.com
Phathom Pharmaceuticals (NASDAQ:PHAT investor five-year losses grow to 69% as the stock sheds US$66m this past week - simplywall.st
Pullback Watch: Is Phathom Pharmaceuticals Inc a strong growth stockJuly 2025 Highlights & Free Reliable Trade Execution Plans - خودرو بانک
Jacobs Levy Equity Management Inc. Invests $3.74 Million in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Fund Flows: Is Phathom Pharmaceuticals Inc. backed by strong institutional buyingJuly 2025 Levels & Fast Moving Trade Plans - khodrobank.com
Profit Review: Is Phathom Pharmaceuticals Inc forming a breakout patternProduct Launch & Daily Risk Controlled Trade Plans - khodrobank.com
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating - 富途牛牛
Phathom says FDA confirmed Voqueza exclusivity through May 2032 - MSN
Phathom Pharmaceuticals officer sells $5573 in stock By Investing.com - Investing.com Canada
Phathom Pharmaceuticals officer sells $5573 in stock - Investing.com
101,520 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Nuveen LLC - MarketBeat
Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High? - Yahoo Finance
Recovery Signals Appearing in Phathom Pharmaceuticals Inc. Charts2025 EndofYear Setup & Weekly High Return Stock Opportunities - beatles.ru
Phathom Pharmaceuticals: The IP Question Is Answered, But Can Management Deliver (Rating Upgrade) - Seeking Alpha
Chart based analysis of Phathom Pharmaceuticals Inc. trendsOil Prices & Capital Protection Trade Alerts - Newser
Is Phathom Pharmaceuticals Inc. stock overvalued or fairly pricedGDP Growth & Expert Verified Stock Movement Alerts - خودرو بانک
Russell Investments Group Ltd. Invests $262,000 in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Aug Breakouts: Can Phathom Pharmaceuticals Inc. weather a recession2025 Technical Overview & Community Verified Watchlist Alerts - خودرو بانک
Signal strength of Phathom Pharmaceuticals Inc. stock in tech scanners2025 Technical Overview & Stepwise Trade Execution Plans - Newser
Visual analytics tools that track Phathom Pharmaceuticals Inc. performanceCEO Change & Consistent Growth Equity Picks - Newser
What the charts say about Phathom Pharmaceuticals Inc. todayWeekly Risk Summary & AI Enhanced Trading Signals - Newser
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
What recovery options are there for Phathom Pharmaceuticals Inc.2025 Volatility Report & Free Technical Confirmation Trade Alerts - Newser
How to forecast Phathom Pharmaceuticals Inc. trends using time series2025 Big Picture & Capital Efficiency Focused Ideas - Newser
Institutional scanner results for Phathom Pharmaceuticals Inc.Earnings Performance Report & AI Driven Stock Movement Reports - Newser
Is Phathom Pharmaceuticals Inc. building a consolidation base2025 Price Momentum & Weekly Hot Stock Watchlists - Newser
Has Phathom Pharmaceuticals Inc. formed a bullish divergenceMarket Performance Summary & Capital Protection Trade Alerts - Newser
How hedge fund analytics apply to Phathom Pharmaceuticals Inc. stock2025 Key Lessons & Daily Volume Surge Trade Alerts - Newser
Detecting support and resistance levels for Phathom Pharmaceuticals Inc.Trade Volume Summary & Growth Focused Entry Point Reports - Newser
What’s next for Phathom Pharmaceuticals Inc. stock priceWeekly Investment Recap & AI Based Buy and Sell Signals - Newser
Will Phathom Pharmaceuticals Inc. stock recover after earningsStock Surge & Accurate Intraday Trading Signals - خودرو بانک
Is Phathom Pharmaceuticals Inc. a turnaround storyWeekly Trade Analysis & Verified Short-Term Trading Plans - خودرو بانک
Is Phathom Pharmaceuticals Inc. backed by strong institutional buyingJuly 2025 Drop Watch & Risk Managed Investment Signals - خودرو بانک
Momentum divergence signals in Phathom Pharmaceuticals Inc. chartWeekly Profit Recap & Precise Swing Trade Entry Alerts - Newser
Dividend Watch: Is Phathom Pharmaceuticals Inc. a top pick in the sector2025 Risk Factors & Verified Short-Term Trading Plans - خودرو بانک
Advanced analytics toolkit walkthrough for Phathom Pharmaceuticals Inc.Earnings Summary Report & Daily Momentum Trading Reports - Newser
Is Phathom Pharmaceuticals Inc. still worth holding after the dipWeekly Trade Report & Community Verified Trade Alerts - Newser
How to read the order book for Phathom Pharmaceuticals Inc.Portfolio Risk Summary & Fast Moving Trade Plans - Newser
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phathom Pharmaceuticals Inc Stock (PHAT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
| Topper James N | Director |
May 12 '25 |
Buy |
3.04 |
12,601 |
38,301 |
48,203 |
| Parikh Asit | Director |
May 06 '25 |
Buy |
2.60 |
5,000 |
13,000 |
90,500 |
| Parikh Asit | Director |
May 07 '25 |
Buy |
2.40 |
5,000 |
11,984 |
95,500 |
| Henderson Molly | CFO and CBO |
Apr 07 '25 |
Sale |
4.55 |
3,678 |
16,740 |
89,868 |
| Parikh Asit | Director |
Mar 13 '25 |
Buy |
4.42 |
10,000 |
44,200 |
85,500 |
1.43%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):